Integrin expression in localized prostate cancer

• Verfasst von: Neuberger, Manuel [VerfasserIn]
• Verfasst von: Frey, Lisa [VerfasserIn]
• Verfasst von: Nitschke, Katja [VerfasserIn]
• Verfasst von: Wessels, Frederik [VerfasserIn]
• Verfasst von: Westhoff, Niklas Christian [VerfasserIn]
• Verfasst von: Waldbillig, Frank [VerfasserIn]
• Verfasst von: Nientiedt, Malin [VerfasserIn]
• Verfasst von: Hartung, Friedrich [VerfasserIn]
• Verfasst von: Hardenberg, Jost von [VerfasserIn]
• Verfasst von: Michel, Maurice Stephan [VerfasserIn]
• Verfasst von: Erben, Philipp [VerfasserIn]
• Verfasst von: Nuhn, Philipp [VerfasserIn]
• Verfasst von: Worst, Thomas [VerfasserIn]
• Titel: Integrin expression in localized prostate cancer
• Titelzusatz: a TCGA and MSKCC cohort-based exploratory in silico analysis
• Verf.angabe: Manuel Neuberger, Lisa Frey, Katja Nitschke, Frederik Wessels, Niklas Westhoff, Frank Waldbillig, Malin Nientiedt, Friedrich Hartung, Jost Von Hardenberg, Maurice Stephan Michel, Philipp Erben, Philipp Nuhn and Thomas Stefan Worst
• E-Jahr: 2023
• Jahr: January 2023
• Umfang: 12 S.
• Fussnoten: Online veröffentlicht 30. Dezember 2022 ; Gesehen am 12.06.2023
• Titel Quelle: Enthalten in: Anticancer research
• Ort Quelle: Kapandriti, Attiki, Greece : International Institute of Anticancer Research, 2004
• Jahr Quelle: 2023
• Band/Heft Quelle: 43(2023), 1 vom: Jan., Seite 417-428
• ISSN Quelle: 1791-7530
• DOI: doi:10.21873/anticanres.16177
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Biomarkers
• Sach-SW: disease-free survival
• Sach-SW: integrins
• Sach-SW: localized prostate cancer
• Sach-SW: prognosis
• K10plus-PPN: 1848769156

Abstract

Background/Aim: Diagnostic and prognostic biomarkers in localized prostate cancer (PC) are insufficient. Treatment stratification relies on prostate-specific antigen, clinical tumor staging and International Society of Urological Pathology (ISUP) grading, whereas molecular profiling remains unused. Integrins (ITG) have an important function in bidirectional signaling and are associated with progression, proliferation, perineural invasion, angiogenesis, metastasis, neuroendocrine differentiation, and a more aggressive disease phenotype in PC. However, ITG subunit expression in localized PC and their utility as prognostic biomarkers has not yet been analyzed. This study aimed to fill this gap and provide a comprehensive overview of ITG expression as well as ITG utility as biomarkers. Patients and Methods: The Cancer Genome Atlas (TCGA) and the Memorial Sloan Kettering Cancer Center (MSKCC) prostate adenocarcinoma cohorts were analyzed regarding ITG expression in correlation to ISUP, N- and American Joint Committee on Cancer (AJCC) stage and were correlated with disease-free survival (DFS). Statistical tests used included the Mann-Whitney U-test, logrank test and uni- and multivariable cox regression analyses. Results: After grouping for ISUP (1 and 2 vs. 3-5), N0 vs. N1 and AJCC stage (≤2 vs. ≥3), multiple ITGs showed significant expression differences. The most consistent results were observed for ITGα4, ITGαX, ITGα11, ITGβ2 and ITGα2. In multivariable cox regression, ITGα2, ITGα10, ITGαD, ITGαB2 (TCGA), ITGα11 and ITGβ4 (MSKCC) were independent predictors of DFS. Conclusion: The utility of ITGs as PC biomarkers was herein shown.